CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma

Tumor Biology

Volumn 32, Issue 1, 2011, Pages 107-111

  Erler, Brian S ^a   Presby, Matthew M ^a   Finch, Meredith ^a   Hodges, Allison ^a   Horowitz, Kari ^a   Topilow, Arthur A ^a   Matulewicz, Theodore ^a  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CD117; Ki 67; Overexpression in NECs; p53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAIN CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 78751572622     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0104-y     Document Type: Article

References (17)

1. S Dirnhofer A Zimpfer P Went 2006 The diagnostic and predictive role of kit (CD117) Ther Umsch 63 273 8 10.1024/0040-5930.63.4.273 16689459
2. L Ferrari S Della Torre P Collini, et al. 2006 Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors Tumori 92 531 5 1:CAS:528:DC%2BD2sXhvFSns7g%3D 17260495
3. K Araki G Ishii T Yokose, et al. 2003 Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung Lung Cancer 40 173 80 10.1016/S0169-5002(03)00034-5 12711118 (Pubitemid 36438718)
4. M Naeem M Dahiya J Clark, et al. 2003 Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis Human Pathol 33 1182 7 10.1053/hupa.2002.129199
5. LD Su DR Fullen L Lowe, et al. 2002 CD117 (KIT receptor) expression in Merkel cell carcinoma Am J Dermatopathol 24 289 93 10.1097/00000372-200208000- 00001 12142606 (Pubitemid 34810303)
6. DJ Gross G Munter M Bitan, et al. 2006 The role of imatinib mesylate (glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R Endocr Relat Cancer 13 535 40 1:CAS:528:DC%2BD28XntF2mtb8%3D 10.1677/erc.1.01124 16728580 (Pubitemid 43886675)
7. LM Krug JP Crapanzano CG Azzoli, et al. 2005 Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein Cancer 103 2128 31 1:CAS:528:DC%2BD2MXkslyltbw%3D 10.1002/cncr.21000 15812822 (Pubitemid 40605121)
8. T Scholzen J Gerdes 2000 The Ki-67 protein: from the known and unknown J Cell Physiol 182 311 22 1:CAS:528:DC%2BD3cXot1Ggsg%3D%3D 10.1002/(SICI)1097- 4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 10653597 (Pubitemid 30054364)
9. KH Paik YH Park B Ryoo, et al. 2006 Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer J Korean Med Sci 21 35 9 1:CAS:528:DC%2BD28XivVGhtbw%3D 10.3346/jkms.2006.21.1. 35 16479062
10. MH Fjallskog MH Lejonklou KE Oberg, et al. 2003 Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors Clin Cancer Res 9 1469 73 12684421
11. AF Li S Tsay W Liang, et al. 2006 Clinical significance of p16INK4A and p53 overexpression in endocrine tumors of the gastrointestinal tract Am J Clin Pathol 126 856 65 1:CAS:528:DC%2BD2sXhtVequg%3D%3D 10.1309/5X6WBYJ3U94EEKNN 17074692
12. A Potti N Moazzam K Ramar, et al. 2003 CD117 (c-kit) overexpression in patients with extensive-stage small-cell lung carcinoma Ann Oncol 14 894 7 1:STN:280:DC%2BD3s3mvFGnuw%3D%3D 10.1093/annonc/mdg253 12796027 (Pubitemid 36827205)
13. U Rohr N Rehfeld L Pflugfelder, et al. 2004 Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer Int J Cancer 111 259 63 1:CAS:528:DC%2BD2cXlvFWnsb0%3D 10.1002/ijc.20252 15197780 (Pubitemid 38924704)
14. P Micke M Basrai A Faldum, et al. 2003 Characterization of c-kit expression in small cell lung cancer: Prognostic and therapeutic implications Clin Cancer Res 9 188 94 1:CAS:528:DC%2BD3sXnt1OltQ%3D%3D 12538468
15. Darwish S, Gregorc V, Ludovini V, et al. p53 overexpression predicts the resistance to chemotherapy but does not improve survival of non small cell lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol. 2001;20: (abstr 3061).
16. ME Couce D Bautista J Costa, et al. 1999 Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms Diagn Mol Pathol 8 71 9 1:STN:280:DyaK1Mvgt1eltA%3D%3D 10.1097/00019606-199906000-00003 10475381 (Pubitemid 29399036)
17. LM Massoni Neto CP Bianchi AM Ab'Saber, et al. 2007 p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas Braz J Med Biol Res 40 1045 53 1:CAS:528:DC%2BD2sXhtFKjsrjL 10.1590/S0100-879X2006005000122 17665040